{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:49:07Z","timestamp":1785293347454,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.cjco.2023.05.008","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T21:28:15Z","timestamp":1685136495000},"page":"629-640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Heart Failure Management in 2023: A Pharmacotherapy- and Lifestyle-Focused Comparison of Current International Guidelines"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4666-1790","authenticated-orcid":false,"given":"Blair J.","family":"MacDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-1528","authenticated-orcid":false,"given":"Ricky","family":"Turgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2023.05.008_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13624","article-title":"Recent advances in pharmacological treatment of heart failure","volume":"51","author":"Iacoviello","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cjco.2023.05.008_bib2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","article-title":"Heart failure with recovered left ventricular ejection fraction: JACC Scientific Expert Panel","volume":"76","author":"Wilcox","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2023.05.008_bib3","first-page":"1342","article-title":"2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure","volume":"33","author":"Ezekowitz","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2023.05.008_bib4","first-page":"531","article-title":"CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2023.05.008_bib5","first-page":"159","article-title":"CCS\/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis","volume":"36","author":"O\u2019Meara","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2023.05.008_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2023.05.008_bib7","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2023.05.008_bib8","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ejhf.2542","article-title":"Head-to-head comparison between recommendations by the ESC and ACC\/AHA\/HFSA heart failure guidelines","volume":"24","author":"Bay\u00e9s-Gen\u00eds","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2023.05.008_bib56","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0140-6736(22)00369-5","article-title":"Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial","volume":"399","author":"Ezekowitz","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2023.05.008_bib50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cjco.2022.11.013","article-title":"Decisional needs and patient treatment preferences for heart failure medications: a scoping review","volume":"5","author":"MacDonald","year":"2022","journal-title":"CJC Open"},{"key":"10.1016\/j.cjco.2023.05.008_bib57","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.11.009","article-title":"Visual transformation for guidelines presentation of the strength of recommendations and the certainty of evidence","volume":"143","author":"Klugar","year":"2022","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cjco.2023.05.008_bib9","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/CIR.0000000000000312","article-title":"Further evolution of the ACC\/AHA Clinical Practice Guideline Recommendation Classification System","volume":"133","author":"Halperin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.05.008_bib10","author":"McMurtry"},{"key":"10.1016\/j.cjco.2023.05.008_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J Cardiol Fail"},{"key":"10.1016\/j.cjco.2023.05.008_bib13","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/eurheartj\/ehaa183","article-title":"Effects of dapagliflozin in DAPA-HF according to background heart failure therapy","volume":"41","author":"Docherty","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2023.05.008_bib14","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2023.05.008_bib15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.120.052926","article-title":"How should we sequence the treatments for heart failure and a reduced ejection fraction?: A redefinition of evidence-based medicine","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.05.008_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008594","article-title":"Heart failure spending function: an investment framework for sequencing and intensification of guideline-directed medical therapies","volume":"15","author":"Allen","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjco.2023.05.008_bib17","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jama.2022.5207","article-title":"Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement","volume":"327","author":"Davidson","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2023.05.008_bib18","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jama.2022.3385","article-title":"Aspirin use to prevent cardiovascular disease and colorectal cancer: updated modeling study for the US Preventive Services Task Force","volume":"327","author":"Dehmer","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2023.05.008_bib19","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1093\/eurheartj\/ehac210","article-title":"Accelerated and personalized therapy for heart failure with reduced ejection fraction","volume":"43","author":"Shen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2023.05.008_bib21","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2023.05.008_bib22","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/ejhf.2301","article-title":"Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other","volume":"23","author":"Greene","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2023.05.008_bib23","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2023.05.008_bib25","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.05.008_bib26","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in Blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.05.008_bib27","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2023.05.008_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.05.008_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2023.05.008_bib30","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/s41591-022-02102-9","article-title":"Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial","volume":"28","author":"Vardeny","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.cjco.2023.05.008_bib31","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A\u00a0living WHO guideline on drugs for covid-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cjco.2023.05.008_bib32","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1016\/j.jacc.2021.04.070","article-title":"Classification of heart failure according to ejection fraction: JACC review topic of the week","volume":"77","author":"Lam","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2023.05.008_bib33","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2023.05.008_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2023.05.008_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2023.05.008_bib36","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.05.008_bib37","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.05.008_bib58","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.05.008_bib59","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2023.05.008_bib38","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.05.008_bib39","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.05.008_bib40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.05.008_bib41","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT\u2014new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.05.008_bib43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cjco.2023.05.008_bib44","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jclinepi.2013.02.004","article-title":"The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses","volume":"66","author":"Mustafa","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cjco.2023.05.008_bib45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjco.2023.05.008_bib46","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ejhf.473","article-title":"Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials","volume":"18","author":"Jankowska","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2023.05.008_bib47","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2023.05.008_bib48","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2023.05.008_bib49","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ejhf.2141","article-title":"Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis","volume":"23","author":"Turgeon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2023.05.008_bib51","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.2147\/PPA.S276328","article-title":"Patient treatment preferences for heart failure medications: a mixed methods study","volume":"14","author":"Trinkley","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.cjco.2023.05.008_bib52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/1071-9164(95)90025-X","article-title":"Use of the Living With Heart Failure Questionnaire to ascertain patients\u2019 perspectives on improvement in quality of life versus risk of drug-induced death","volume":"1","author":"Rector","year":"1995","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjco.2023.05.008_bib53","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.cardfail.2016.05.004","article-title":"Attitudes of patients and prescribing clinicians to polypharmacy and medication withdrawal in heart failure","volume":"22","author":"Hopper","year":"2016","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjco.2023.05.008_bib54","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007070","article-title":"Show me the money: patients\u2019 perspectives on a decision aid for sacubitril\/valsartan addressing out-of-pocket cost","volume":"13","author":"Dickert","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X23001233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X23001233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:11:18Z","timestamp":1762902678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X23001233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2589790X23001233"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2023.05.008","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart Failure Management in 2023: A Pharmacotherapy- and Lifestyle-Focused Comparison of Current International Guidelines","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2023.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}